| pubmed-article:369695 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:369695 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:369695 | lifeskim:mentions | umls-concept:C0003993 | lld:lifeskim |
| pubmed-article:369695 | lifeskim:mentions | umls-concept:C0025677 | lld:lifeskim |
| pubmed-article:369695 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:369695 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:369695 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:369695 | lifeskim:mentions | umls-concept:C1705294 | lld:lifeskim |
| pubmed-article:369695 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:369695 | pubmed:dateCreated | 1979-5-23 | lld:pubmed |
| pubmed-article:369695 | pubmed:abstractText | The combination of sequential L-asparaginase and methotrexate (MTX) was evaluated in 33 patients with advanced refractory breast cancer. There were nine partial responses and one complete response, giving an overall response rate of 30% and a median duration of response of 8 months. Five of 17 patients (28%) who had received prior MTX at doses of less than 50 mg/m2 responded. Toxicity was acceptable. Moderate-to-severe stomatitis occurred in most patients and was the dose-limiting factor. Myelosuppression was minimal until the dose of MTX was escalated to greater than or equal to 180 mg/m2. The maximum tolerated dose of MTX was 280 mg/m2 and the median toxic dose was 220 mg/m2. These data indicate a selective "rescue" from MTX damage to normal target tissue by L-asparaginase. The antitumor effect observed even in patients who had been previously exposed to conventional doses of MTX suggests a possible improved therapeutic index of MTX given sequentially with L-asparaginase in this combination. | lld:pubmed |
| pubmed-article:369695 | pubmed:language | eng | lld:pubmed |
| pubmed-article:369695 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:369695 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:369695 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:369695 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:369695 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:369695 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:369695 | pubmed:issn | 0361-5960 | lld:pubmed |
| pubmed-article:369695 | pubmed:author | pubmed-author:BodeyG PGP | lld:pubmed |
| pubmed-article:369695 | pubmed:author | pubmed-author:BlumenscheinG... | lld:pubmed |
| pubmed-article:369695 | pubmed:author | pubmed-author:TashimaC KCK | lld:pubmed |
| pubmed-article:369695 | pubmed:author | pubmed-author:HortobagyiG... | lld:pubmed |
| pubmed-article:369695 | pubmed:author | pubmed-author:BuzdarA UAU | lld:pubmed |
| pubmed-article:369695 | pubmed:author | pubmed-author:YapH YHY | lld:pubmed |
| pubmed-article:369695 | pubmed:author | pubmed-author:BenjaminR SRS | lld:pubmed |
| pubmed-article:369695 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:369695 | pubmed:volume | 63 | lld:pubmed |
| pubmed-article:369695 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:369695 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:369695 | pubmed:pagination | 77-83 | lld:pubmed |
| pubmed-article:369695 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:369695 | pubmed:meshHeading | pubmed-meshheading:369695-H... | lld:pubmed |
| pubmed-article:369695 | pubmed:meshHeading | pubmed-meshheading:369695-B... | lld:pubmed |
| pubmed-article:369695 | pubmed:meshHeading | pubmed-meshheading:369695-A... | lld:pubmed |
| pubmed-article:369695 | pubmed:meshHeading | pubmed-meshheading:369695-F... | lld:pubmed |
| pubmed-article:369695 | pubmed:meshHeading | pubmed-meshheading:369695-A... | lld:pubmed |
| pubmed-article:369695 | pubmed:meshHeading | pubmed-meshheading:369695-N... | lld:pubmed |
| pubmed-article:369695 | pubmed:meshHeading | pubmed-meshheading:369695-B... | lld:pubmed |
| pubmed-article:369695 | pubmed:meshHeading | pubmed-meshheading:369695-M... | lld:pubmed |
| pubmed-article:369695 | pubmed:meshHeading | pubmed-meshheading:369695-T... | lld:pubmed |
| pubmed-article:369695 | pubmed:meshHeading | pubmed-meshheading:369695-M... | lld:pubmed |
| pubmed-article:369695 | pubmed:meshHeading | pubmed-meshheading:369695-D... | lld:pubmed |
| pubmed-article:369695 | pubmed:meshHeading | pubmed-meshheading:369695-C... | lld:pubmed |
| pubmed-article:369695 | pubmed:meshHeading | pubmed-meshheading:369695-D... | lld:pubmed |
| pubmed-article:369695 | pubmed:meshHeading | pubmed-meshheading:369695-A... | lld:pubmed |
| pubmed-article:369695 | pubmed:year | 1979 | lld:pubmed |
| pubmed-article:369695 | pubmed:articleTitle | Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. | lld:pubmed |
| pubmed-article:369695 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:369695 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:369695 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:369695 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:369695 | lld:pubmed |
